RT Journal Article
SR Electronic
T1 A multiplexed Cas13-based assay with point-of-care attributes for simultaneous COVID-19 diagnosis and variant surveillance
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.03.17.22272589
DO 10.1101/2022.03.17.22272589
A1 Maturada Patchsung
A1 Aimorn Homchan
A1 Kanokpol Aphicho
A1 Surased Suraritdechachai
A1 Thanyapat Wanitchanon
A1 Archiraya Pattama
A1 Khomkrit Sappakhaw
A1 Piyachat Meesawat
A1 Thanakrit Wongsatit
A1 Artittaya Athipanyasilp
A1 Krittapas Jantarug
A1 Niracha Athipanyasilp
A1 Juthamas Buahom
A1 Supapat Visanpattanasin
A1 Nootaree Niljianskul
A1 Pimchai Chaiyen
A1 Ruchanok Tinikul
A1 Nuanjun Wichukchinda
A1 Surakameth Mahasirimongkol
A1 Rujipas Sirijatuphat
A1 Nasikarn Angkasekwinai
A1 Michael A. Crone
A1 Paul S. Freemont
A1 Julia Joung
A1 Alim Ladha
A1 Omar Abudayyeh
A1 Jonathan Gootenberg
A1 Feng Zhang
A1 Claire Chewapreecha
A1 Sittinan Chanarat
A1 Navin Horthongkham
A1 Danaya Pakotiprapha
A1 Chayasith Uttamapinant
YR 2022
UL http://medrxiv.org/content/early/2022/03/18/2022.03.17.22272589.abstract
AB Point-of-care (POC) nucleic acid detection technologies are poised to aid gold-standard technologies in controlling the COVID-19 pandemic, yet shortcomings in the capability to perform critically needed complex detection—such as multiplexed detection for viral variant surveillance—may limit their widespread adoption. Herein, we developed a robust multiplexed CRISPR-based detection using LwaCas13a and PsmCas13b to simultaneously diagnose SARS-CoV-2 infection and pinpoint the causative SARS-CoV-2 variant of concern (VOC)— including globally dominant VOCs Delta (B.1.617.2) and Omicron (B.1.1.529)—all while maintaining high levels of accuracy upon the detection of multiple SARS-CoV-2 gene targets. The platform has several attributes suitable for POC use: premixed, freeze-dried reagents for easy use and storage; convenient direct-to-eye or smartphone-based readouts; and a one-pot variant of the multiplexed detection. To reduce reliance on proprietary reagents and enable sustainable use of such a technology in low- and middle-income countries, we locally produced and formulated our own recombinase polymerase amplification reaction and demonstrated its equivalent efficiency to commercial counterparts. Our tool—CRISPR-based detection for simultaneous COVID-19 diagnosis and variant surveillance which can be locally manufactured—may enable sustainable use of CRISPR diagnostics technologies for COVID- 19 and other diseases in POC settings.Competing Interest StatementO.A., J.G., and F.Z. are co-founders of Sherlock Biosciences and Pine Trees Health. M.A.C. and P.S.F. have acted as consultants for Analytik Jena GmbH. M.P., A.H., K.A., S.S., D.P., and C.U. have filed a patent in Thailand on the formulations for multiplexed detection of SARS-CoV-2 RNA. The remaining authors declare no competing interests.Funding StatementThe project is financially supported by PTT, PTTEP, Kasikorn Bank, Siam Commercial Bank, GPSC, VISTEC, Siriraj Hospital, Mahidol University, and Department of Medical Sciences, Ministry of Public Health. C.C. was funded by Wellcome International Intermediate Fellowship (216457/Z/19/Z) and Sanger International Fellowship. M.A.C and P.S.F. acknowledge funding from UKRI-EPSRC (EP/R014000/1, EP/S001859/1), UKRI-BBSRC (BB/M025632/1) and the UK Dementia Research Institute.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval of the study was given by the Siriraj Institutional Review Board (COA: Si 339/2020 and Si 424/2020).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe main data supporting the results in this study are available within the paper and its supplementary information. Raw datasets generated and analysed during the study are available from the corresponding authors upon reasonable request.